AXLA

In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on Axcella Health (AXLA - Research Report), with a price target of $9.00. The company's shares closed yesterday at $1.11.According to TipRanks, LeBoyer is a 2-star analyst with an average return of -0.5% and a 27.08% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Axcella Health, and Ayala Pharmaceuticals.Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $6.80, implying a 515.38% upside from current levels.
https://www.tipranks.com/news/blurbs/noble-financial-keeps-their-buy-rating-on-axcella-health-axla-2?utm_source=advfn.com&utm_medium=referral